This was a phase III, randomized withdrawal, double-blind, placebo-controlled, enriched enrollment, parallel-group, multicenter study intended to demonstrate the safety, tolerability, and analgesic efficacy of oxycodone DETERx® (Xtampza™ ER) compared with matching placebo.
This post hoc analysis was performed using data from a subpopulation of enrolled patients who were ≥65 years of age. The study enrolled male and female patients with a clinical diagnosis of moderate-to-severe chronic low back pain for a minimum of 6 months prior to screening who required around-the-clock opioid therapy. To be eligible for enrollment, patients were required to have an average 24-h pain intensity score of ≥5 and ≤9 on an 11-point (0–10) Pain Intensity—Numerical Rating Scale at the screening visit. The study enrolled both opioid-experienced and opioid-naïve patients. The study consisted of an open-label titration phase followed by a 12-week double-blind maintenance phase. The dose range was 40–160 mg oxycodone hydrochloride equivalent per day. This post hoc analysis evaluated the safety, tolerability, and effectiveness of oxycodone DETERx among patients ≥65 years of age. The effectiveness of oxycodone DETERx was evaluated based on average pain intensity scores, Patient Global Impression of Change, responder analysis, and Kaplan–Meier survival analysis. The safety and tolerability of oxycodone DETERx were also evaluated. Patients were randomized to either oxycodone DETERx or placebo using a blocked randomization scheme in a 1:1 ratio. Randomization was stratified by previous opioid use (naïve or experienced). The study drug was coded in a manner that maintained the blinding. Study personnel and patients remained blinded to the assigned treatments throughout the study.
For this post-hoc analysis, the intent-to-treat and randomized safety populations included 52 patients ≥65 years old, 26 each in the oxycodone DETERx and placebo groups, who participated in the study during the titration phase and were randomized to the double-blind maintenance phase. Clinically important pain reduction from screening was achieved with oxycodone DETERx, with the median pain intensity score decreasing from 7.50 at screening to 2.69 at Week 12. A clinically meaningful treatment difference of −0.9 in pain score between oxycodone DETERx and placebo was observed. All 18 elderly patients who completed the study reported improvement in pain, with 62% showing ≥30% improvement and 54% showing ≥50% improvement in pain intensity compared with patients on placebo (p = 0.0128 and p = 0.0501, respectively). Patients on oxycodone DETERx remained in the study longer than those on placebo. Of the 26 patients ≥65 years old randomized to continue oxycodone DETERx during the double-blind maintenance phase, 18 (69%) completed the study; only two patients (8%) in the oxycodone DETERx group discontinued due to adverse events. The safety and tolerability profiles showed no new or unexpected safety concerns. The adverse event profiles were similar between the titration and double-blind maintenance phases.
Oxycodone DETERx was efficacious and generally well tolerated in patients ≥65 years old.
The study was registered with ClinicalTrials.gov (NCT01685684).
Global Industry Analysts, Inc. Report; 2011. http://www.prweb.com/pdfdownload/8052240.pdf. Accessed 6 June 2017.
Newsroom Archive. 2010 census shows 65 and older population growing faster than total U.S. population. https://www.census.gov/newsroom/releases/archives/2010_census/cb11-cn192.html. Accessed 6 June 2017.
Center for Drug Evaluation and Research (CDER). Guidance for industry: size, shape, and other physical attributes of generic tablets and capsules. Rockville: U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research; 2015.
Coluzzi PH, Fairbairn BS. The management of pain in terminally ill cancer patients with difficulty swallowing. Am J Hosp Palliat Med. 1999;16(6):731–7. CrossRef
Zorba Paster R. Chronic pain management issues in the primary care setting and the utility of long-acting opioids. Expert Opin Pharmacother. 2010;11(11):1823–33. CrossRef
Kopecky E, Fleming A, Findlen K, et al. Oxycodone DETERx, an extended-release, abuse-deterrent formulation for management of patients with chronic pain and chronic pain with dysphagia. J Pain. 2014;15(4):S90. CrossRef
Ferrell B, Ferrell BA. Pain in the elderly: a report of the Task Force on Pain in the Elderly of the International Association for the Study of Pain. Seattle: IASP Press; 1996.
McClean WJ, Higginbotham NH. Prevalence of pain among nursing home residents in rural New South Wales. Med J Aust. 2002;177(1):17–20. PubMed
AGS Panel on Persistent Pain in Older Persons. The management of persistent pain in older persons. J Am Geriatr Soc. 2002;50(S6):205–24. CrossRef
Ferrell B, Argoff CE, Epplin J, et al. Pharmacological management of persistent pain in older persons. J Am Geriatr Soc. 2009;57(8):1331–46. doi: 10.1111/j.1532-5415.2009.02376.x.
Eisenberg E, McNicol ED, Carr DB. Efficacy and safety of opioid agonists in the treatment of neuropathic pain of nonmalignant origin. J Am Med Assoc. 2005;293(24):3043–52. CrossRef
Trescot AM, Helm S, Hansen H, et al. Opioids in the management of chronic non-cancer pain: an update of American Society of the Interventional Pain Physicians’ (ASIPP) Guidelines. Pain Physician. 2008;11(2 Suppl):S5–62. PubMed
Benyamin R, Trescot AM, Datta S, Buenaventura R, Adlaka R, Sehgal N, et al. Opioid complications and side effects. Pain Physician. 2008;11(2 Suppl):S105–20. PubMed
Rao A, Cohen HJ. Symptom management in the elderly cancer patient: fatigue, pain, and depression. J Natl Cancer Inst Monogr. 2004;2004(32):150–7. CrossRef
OxyContin [package insert] Purdue Pharma L.P., Stamford, CT, 2007. http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020553s059lbl.pdf. Accessed 6 June 2017.
Opana ER [package insert] Endo Pharmaceuticals Inc., Chadds Ford, PA. 2012. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/201655s004lbl.pdf. Accessed 6 June 2017.
Hysingla ER [package insert] Purdue Pharma L.P., Stamford, CT. 2014. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206627s000lbl.pdf. Accessed 6 June 2017.
Embeda [medication guide] Pfizer Inc., New York, NY. 2014. http://www.fda.gov/downloads/Drugs/DrugSafety/UCM179172.pdf. Accessed 6 June 2017.
Troxyca ER [medication guide] Pfizer, Inc., New York, NY. 2016. http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207621s004lbl.pdf#page=32. Accessed 6 June 2017.
SAS Software, Version 9.4 of the SAS System for Windows. Copyright © 2014 SAS Institute Inc.
Zohydro ER [medical review] Zogenix Inc., Emeryville, CA. 2013. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/202880Orig1s000MedR.pdf. Accessed 6 June 2017.
- Tolerability, Safety, and Effectiveness of Oxycodone DETERx in Elderly Patients ≥65 Years of Age with Chronic Low Back Pain: A Randomized Controlled Trial
Ernest A. Kopecky
- Springer International Publishing
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
e.Med Kampagnen-Visual, Mail Icon II